Clinical Trials Browser

Phase 2 × Interventional × epacadostat × Clear all

NCT04463771 2025-12-10

POD1UM-204

Phase 2 Active not recruiting

Neoplasm Metastasis, Endometrial Neoplasms

NCT03532295 2025-11-21

Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Phase 2 Completed

51 enrolled 16 charts

Glioblastoma, Glioma

NCT03322540 2025-08-22

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

Phase 2 Completed

154 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03414229 2025-05-02

A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Phase 2 Active not recruiting

30 enrolled 11 charts

Sarcoma

NCT03006302 2024-10-08

Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

Phase 2 Completed

41 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03602586 2024-07-26

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Phase 2 Completed

14 enrolled 12 charts

Ovarian Neoplasms

NCT03291054 2024-06-11

Epacadostat and Pembrolizumab in Patients With GIST

Phase 2 Terminated

1 enrolled 1 chart

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT03196232 2024-01-23

Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer

Phase 2 Completed

3 enrolled 12 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT03823131 2023-05-09

Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

Phase 2 Terminated

14 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck

NCT03592407 2022-03-08

Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer

Phase 2 Withdrawn

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

NCT03322566 2022-01-24

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Phase 2 Completed

233 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03832673 2021-02-26

PECULIAR

Phase 2 Withdrawn

Neoplasms

NCT03463161 2020-01-27

ORKA

Phase 2 Terminated

2 enrolled 5 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02364076 2019-12-13

Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma

Phase 2 Unknown

45 enrolled 10 charts

Thymoma, Thymus Neoplasms

NCT03432676 2019-05-30

Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03325465 2019-04-22

Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck

Phase 2 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01685255 2019-03-11

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

Phase 2 Terminated

Neoplasms, Ovarian Neoplasms

NCT03402880 2018-10-10

ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase 2 Withdrawn

Extensive Stage Small Cell Lung Carcinoma

NCT01961115 2018-06-08

Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma

Phase 2 Completed

11 enrolled 12 charts

Uveal Melanoma, Melanoma

NCT03238638 2018-01-04

A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy

Phase 2 Withdrawn

Head and Neck Neoplasms

NCT01822691 2016-01-18

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

Phase 2 Completed

15 enrolled 8 charts

Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute